Compare PLBY & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLBY | MDWD |
|---|---|---|
| Founded | 1953 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.8M | 238.5M |
| IPO Year | N/A | 2014 |
| Metric | PLBY | MDWD |
|---|---|---|
| Price | $1.84 | $18.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 1.3M | 82.4K |
| Earning Date | 11-12-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,510,000.00 | $20,932,000.00 |
| Revenue This Year | $4.97 | $15.89 |
| Revenue Next Year | $8.38 | $25.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.15 |
| 52 Week Low | $0.90 | $14.14 |
| 52 Week High | $2.53 | $22.51 |
| Indicator | PLBY | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 53.42 |
| Support Level | $1.70 | $18.55 |
| Resistance Level | $1.93 | $18.96 |
| Average True Range (ATR) | 0.15 | 0.53 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 16.27 | 27.38 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.